Cardiac autonomic neuropathy in patients with SGA-treated schizophrenia: a randomized controlled trial of 30 weeks’ treatment with semaglutide

Abstract Background Individuals with schizophrenia suffer from reduced life expectancy, primarily due to obesity-related metabolic disorders and cardiovascular disease (CVD). The presence of cardiac autonomic neuropathy (CAN) may contribute to CVD, but CAN is reversible, and it may improve following...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Ashok Ainkaran Ganeshalingam, Nicolai Gundtoft Uhrenholt, Sidse Arnfred, Peter Gæde, Andreas Kristian Pedersen, Niels Bilenberg, Jan Frystyk
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BioMed Central 2026-01-01
Colecção:	Cardiovascular Diabetology. Endocrinology Reports
Assuntos:	Schizophrenia Prediabetes Prevention Cardiovascular autonomic neuropathy Antipsychotic treatment Obesity
Acesso em linha:	https://doi.org/10.1186/s40842-025-00258-0
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!